Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease
55% of participants in national
61% endured an invasive procedure for diagnosis
Authors call for improved physician education, practical clinical guidelines and better diagnostic tools
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180118005528/en/
Up to 200,000 patients in
- Forty-three percent of survey respondents endured a year or more between the time they first experienced symptoms (most commonly shortness of breath and cough) and the time they received a diagnosis; nearly one in five (19 percent) endured three or more years.
- Fifty-five percent reported at least one misdiagnosis prior to receiving an accurate diagnosis; more than a third (38 percent) reported at least two misdiagnoses.
- Among those with IPF, more than one in five (21 percent) reported treatment during the diagnostic process with systemic corticosteroids, a potentially harmful therapy for IPF patients.
"Our results show that the typical diagnostic experience for patients
with ILD, including IPF, is characterized by considerable delays,
frequent misdiagnosis, exposure to costly and invasive diagnostic
procedures and substantial use of healthcare resources," said lead
Among survey participants, 47 percent of whom reported having IPF, an accurate diagnosis typically involved a substantial use of healthcare resources:
- Most ILD diagnoses (88 percent) were made by a pulmonologist, however multiple primary care physician (PCP) visits were the norm, with 30 percent of patients seeing a PCP four or more times before being referred to a specialist.
- On average, respondents endured six pulmonary lung function tests, five chest X-rays and two bronchoscopies before receiving a diagnosis.
- Sixty-one percent of patients endured invasive diagnostic procedures, including surgical lung biopsy.
The survey also revealed the significant emotional and financial toll of the diagnostic journey for patients with ILD:
- More than 80 percent of respondents reported emotional stress due to the ongoing uncertainty regarding their diagnosis.
- Nearly one third (28 percent) reported that time spent attending medical appointments and undergoing diagnostic procedures contributed to their decision to apply for disability benefits or retire.
"The publication of these findings underscores the tremendous need for
patients with suspected IPF to get clearer answers faster so that they
can receive the treatment they need and avoid potentially harmful
diagnostic procedures and treatment," said
Independent healthcare-research organization Outcomes Insights conducted
the INTENSITY survey from
About Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis
Each year in
About the Envisia Genomic Classifier
The Envisia Genomic Classifier provides answers that improve physicians'
ability to differentiate idiopathic pulmonary fibrosis (IPF) from other
interstitial lung diseases (ILDs) without the need for invasive, risky
and costly surgery. The 190-gene classifier was commercially introduced
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that the use of the Envisia classifier to enable diagnosis of idiopathic pulmonary fibrosis, without the need for invasive, risky and costly surgical procedure; Envisia's ability to further give physicians confidence in using our test in lieu of surgery; and Envisia's ability to significantly improve patient care and reduce healthcare costs. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: benefits of our tests, the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
News Provided by Acquire Media